BI, Lilly drug reduces blood sugar over long term
LISBON, Portugal — A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.
BI and Lilly presented data from their 102-week phase-3 study of Tradjenta (linagliptin) at the European Association for the Study of Diabetes’ 47th annual meeting in Lisbon, Portugal, showing that the drug lowered HbA1C levels by 0.8% over the long term. The drug is marketed in Europe under the name Trajenta.
"These results show that the efficacy achieved by linagliptin is reliable and meaningful in a clinical setting, but also that it is durable over the long term," said David Owens, a medical professor at Cardiff University School of Medicine, in Wales.
In the 2,121-patient study, patients were given Tradjenta, Tradjenta with metformin or Takeda’s Actos (pioglitazone) or Trajdenta with metformin and sulphonylurea.
Emerson Group hires CVS’ Elizabeth Karvonen
WAYNE, Pa. — Former CVS/pharmacy product development manager Elizabeth Karvonen has joined the Emerson Group, where she will work on the beauty and personal care businesses at CVS/pharmacy.
Prior to joining the Emerson Group, Karvonen was a product development manager at CVS/pharmacy, where she developed private-label beauty and personal care products. In her first year, she developed more than 160 private-label products and was responsible for supply chain and logistics for the private-label beauty and personal care categories.
Express Scripts to provide services for cancer side effect treatment
ST. LOUIS — Pharmacy benefit manager Express Scripts will provide services for patients using a drug to manage a debilitating side effect of many anti-cancer treatments, ESI said.
The PBM announced that it would provide services for Access Pharmaceuticals’ MuGard through its HealthBridge Pharma & Biotech division. MuGard is an oral wound rinse and coating used to manage oral mucositis. ESI said it would be the exclusive provider of third-party logistics, or 3PL services for the product, and the preferred specialty pharmacy for patients using it, through subsidiary CuraScript.
"We are excited about working with Access Pharmaceuticals as a fully integrated supply chain partner," ESI VP strategy and contracting for pharmaceuticals and biotechnology Kevin Cast said. "The award of an exclusive 3PL position and preferred specialty pharmacy position for MuGard is absolute validation of our commitment to providing vital access solutions for pharmaceutical and biotech organizations."